Commonwealth Equity Services’s Kyverna Therapeutics KYTX Stock Holding History

Commonwealth Equity Services’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$106K	Buy	+11,850	New	+$105K	﹤0.01%	4248

Other funds holding KYTX

GordonMD Global Investments Beverely Hills, California $207M AUM

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Commonwealth Equity Services's KYTX Position: Q2 2026 in Review

Commonwealth Equity Services opened a new position in Kyverna Therapeutics (KYTX) in Q2 2026: 11,850 shares worth $106K. The stake represents ﹤0.01% of the portfolio and ranks #4248 among its holdings.

120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

Commonwealth Equity Services held 11,850 shares of Kyverna Therapeutics worth $106K as of Q2 2026.
Kyverna Therapeutics was a new Commonwealth Equity Services position in Q2 2026.
Kyverna Therapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #4248 holding.
120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.